AKT1 and cancer: Therefore, drugs targeting the PI3K/Akt and MAPK pathways now appear to be promising candidates for cancer immunotherapy with intrinsic antitumor effect on cancer cells, and more studies are needed to further unravel the role of these cellular pathways in different immune microenvironments.